Rare diseases
Investigational molecules
Locations
Safety and Tolerability of Lutetium‑177 Vipivotide Tetraxetan Combined with Gozetotide in Women with Metastatic Triple‑Negative Breast Cancer
GermanyStudy of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer
AustriaStudy on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer
CyprusStudy of Lutetium (177Lu) Vipivotide Tetraxetan and Ipilimumab for Men with Very High-Risk Prostate Cancer
GermanyStudy on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer
GermanyStudy Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer
AustriaStudy on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer
AustriaStudy on the Safety and Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
PolandStudy on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function
FranceStudy on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer
CzechiaTell us about your condition – we search every trial in Europe and connect you with the right site.
